

# Clinical trials of angiotensin-receptor blockers for heart failure in patients with preserved-LVEF heart failure

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 angiotensin receptor blocker

| Trial   | Treatments  | Patients   | Trials design and methods  |
|---|---|--|--|
| <b>valsartan vs no valsartan</b>  |   |  |  |
| <b>VALIDD , 2007</b><br>[NCT00170924]<br>n=186/198<br>follow-up: 38 weeks                     | valsartan titrated up to 320 mg once daily<br>versus<br>placebo | Patients with hypertension and evidence of diastolic dysfunction                         | Parallel groups<br>double blind<br>USA, canada   |
| <b>candesartan vs placebo</b>   |   |  |  |
| <b>CHARM preserved , 2003</b><br>n=1514/1509<br>follow-up: 36.6 months                        | candesartan target dose 32 mg once daily<br>versus<br>placebo   | patients with NYHA II-IV heart failure and LVEF higher than 40%                          | Parallel groups<br>double blind<br>26 countries  |
| <b>ibesartan vs placebo</b>   |   |  |  |
| <b>I-PRESERVE (McMurray) , 2008</b><br>[NCT00095238]<br>n=2067/2061<br>follow-up: 49.5 months | ibersatan 300mg daily<br>versus<br>placebo                      | patients with NYHA II, III, or IV heart failure and an ejection fraction of at least 45% | Parallel groups<br>double blind<br>Western Europe, Eastern Europe, North America, South America, South Africa, and Australia |

## References

### VALIDD, 2007:

American College of Cardiology Annual Scientific Session, New Orleans, LA, March 2007. [0]

Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcire Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007 Jun 23;369:2079-87 [17586303]

### CHARM preserved, 2003:

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003 Sep 6;362:777-81 [13678871]

### I-PRESERVE (McMurray), 2008:

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Dec 4;359:2456-67 [19001508] [10.1056/NEJMoa0805450](https://doi.org/10.1056/NEJMoa0805450)

McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008 Feb;10:149-56 [18279770]

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med* 2008 Dec 4;359:2456-67 [[19001508](#)]

## 2 angiotensin receptor neprilysin inhibitor

| Trial   | Treatments   | Patients   | Trials design and methods |
|---|--|--|---------------------------|
| <b>LCZ696 vs Valsartan</b>  |  |  |                           |
| <b>PARAGON-HF</b> <i>ongoing</i><br>[NCT01920711]<br>n=4600<br>follow-up: | LCZ696 target dose 200mg bid<br>versus<br>Valsartan target dose of 160 mg b.i.d. | patients with HF with preserved ejection<br>fraction | d                         |

## References

### PARAGON-HF, :

Rossi A, Gheorghiadu M, Triposkiadis F, Solomon SD, Pieske B, Butler J Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. *Circ Heart Fail* 2014 Nov;7:1042-9 [[25415957](#)] [10.1161/CIRCHEARTFAILURE.114.001276](#)

Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. *JACC Heart Fail* 2017;5:471-482 [[28662936](#)]

## 3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.